All In Biotech

Drug Trial Radar · NCT01169259

Vitamin D and Omega-3 Trial (VITAL)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 25,871 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

25,871

Actual

Start

Jul 2010

Primary completion

Nov 10, 2018

Study completion Mar 2031

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements (ODS); National Institute of Neurological Disorders and Stroke (NINDS); National Center for Complementary and Integrative Health (NCCIH); Pharmavite LLC; Pronova BioPharma; BASF
First posted
Jul 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The 5-year intervention phase (study pill-taking, median 5.3 years) has ended; post-intervention observational follow-up of study participants is ongoing.

Conditions

  • Cancer
  • Cardiovascular Disease

Interventions

  • vitamin D3Dietary supplement

    Vitamin D3 (cholecalciferol), 2000 IU per day.

  • omega-3 fatty acids (fish oil)Drug

    Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

  • Vitamin D3 placeboDietary supplement

    Vitamin D placebo

  • Fish oil placeboDietary supplement

    Fish oil placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Invasive Cancer of Any TypeTime frame: 5 years
  2. Number of Participants With a Major Cardiovascular EventTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.